In the seven major pharmaceutical markets (7MM*), less than half of non-alcoholic steatohepatitis (NASH) cases were diagnosed in 2019, says GlobalData, a leading data and analytics company. Increased physician awareness and the implementation of systematic screening programs that are more widely received will likely help to close the gap between diagnosed and undiagnosed cases.

The company’s latest report, ‘Non-Alcoholic Steatohepatitis: Epidemiology Forecast to 2029’, revealed that less than half of NASH cases were diagnosed in 2019 in men and women of all ages, with the US experiencing the most undiagnosed cases due to the large number of NASH cases in this market.

Natasha Karim, MPH, Managing Epidemiologist at GlobalData comments: “Accurate and timely identification of NASH cases in the primary care setting is critical for improving patient outcomes. Future efforts should prioritize addressing gaps in physician awareness and developing less-invasive gold standard diagnostic methods for NASH other than a liver biopsy.”

* 7MM: The US, France, Germany, Italy, Spain, the UK and Japan

Information based on GlobalData’s report: ‘Non-Alcoholic Steatohepatitis: Epidemiology Forecast to 2029’